Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AC2993 LAR: AMLN said it would start later this month a Phase II trial of monthly injections of AC2993 LAR . AC2993 LAR is being co-developed with Alkermes Inc.

Amylin Pharmaceuticals Inc. (AMLN), San Diego, Calif.
Product:

Read the full 86 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE